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Background
Because acute liver failure (ALF) patients share many clinical features with severe sepsis
and septic shock, identifying bacterial infection clinically in ALF patients is challenging. Procalcitonin (PCT) has proven to be a useful marker in detecting bacterial infection. We sought
to determine whether PCT discriminated between presence and absence of infection in
patients with ALF.
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Method

Published: September 22, 2015

Retrospective analysis of data and samples of 115 ALF patients from the United States
Acute Liver Failure Study Group randomly selected from 1863 patients were classified for
disease severity and ALF etiology. Twenty uninfected chronic liver disease (CLD) subjects
served as controls.
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Results
Procalcitonin concentrations in most samples were elevated, with median values for all ALF
groups near or above a 2.0 ng/mL cut-off that generally indicates severe sepsis. While PCT
concentrations increased somewhat with apparent liver injury severity, there were no differences in PCT levels between the pre-defined severity groups–non-SIRS and SIRS groups
with no documented infections and Severe Sepsis and Septic Shock groups with documented infections, (p = 0.169). PCT values from CLD patients differed from all ALF groups
(median CLD PCT value 0.104 ng/mL, (p 0.001)). Subjects with acetaminophen (APAP)
toxicity, many without evidence of infection, demonstrated median PCT >2.0 ng/mL, regardless of SIRS features, while some culture positive subjects had PCT values <2.0 ng/mL.
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Summary/Conclusions
While PCT appears to be a robust assay for detecting bacterial infection in the general population, there was poor discrimination between ALF patients with or without bacterial infection presumably because of the massive inflammation observed. Severe hepatocyte
necrosis with inflammation results in elevated PCT levels, rendering this biomarker unreliable in the ALF setting.

Introduction
Patients with acute liver failure (ALF) have an increased risk of infection approaching 80%
thus predisposing to sepsis-related multi-organ failure [1–3]. Infections have been shown to
worsen hepatic encephalopathy (HE) and are one of the most common causes of multi-organ
dysfunction and death in ALF [3, 4].
Signs and symptoms of ALF closely mimic those of sepsis making it difficult to accurately
identify infection in this setting. The diagnosis of infection or sepsis (usually based upon a positive culture) is often delayed or not detected, even when presumptive evidence is very strong.
Identification of a bacterial infection by culture requires 48–72 hours to complete and the efficacy of prophylactic antibiotics to contain an established infection remains difficult to prove. A
more rapid method to identify infection is a worthwhile goal.
Procalcitonin (PCT) is a biomarker for detection of bacterial infection that has shown early
promise. PCT consists of 116 amino acids and has a MW of 14.5 kDa. A precursor of calcitonin, the primary source of PCT is the parafollicular C cells of the thyroid gland. Calcitonin has
a hypocalcemic and hypophosphatemic effect that inhibits bone resorption and stimulates
excretion of phosphorus, calcium, and sodium by the kidney and is used as a biomarker of
medullary thyroid cancer but its relation to systemic inflammation remains unclear [5–8].
In studies of patients with sepsis, pneumonia, and other types of infections, PCT has been
shown to be a reliable and rapidly available indicator of bacterial infection, useful in guiding
antimicrobial therapy. PCT has been examined in patients who have had a liver transplant and
in patients hospitalized with chronic liver disease (cirrhosis; CLD), but there are few studies of
patients with ALF. [9–14].
In this study, we sought to determine whether PCT would aid in the identification of infection in ALF patients, since distinguishing sepsis from ALF without infection has prognostic
and therapeutic implications. We utilized the extensive registry and serum bank of the U. S.
Acute Liver Failure Study Group (USALFSG) as well as 2 local repositories for CLD control
sera, to address this question.

Materials and Methods
Study Population
This study included patients prospectively enrolled in the US Acute Liver Failure Study (established in January 1998). Additionally, data and sera from two other repositories related to CLD
were accessed to provide control groups. A total of 1863 adult ALF patients were enrolled from
23 tertiary care centers within the US between Jan. 1998 and Oct. 2010. Inclusion criteria defining ALF were the presence of coagulopathy (PT > 15 seconds or INR 1.5 IU) and any grade
of hepatic encephalopathy (HE) that had occurred within 26 weeks of the first onset of symptoms. Enrolled patients may not have any CLD or cirrhosis, with the exception of certain
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patients with chronic hepatitis B or Wilson’s disease [15]. Written informed consent was
obtained for each subject from the next of kin because of altered mental status due to HE. All
centers were in compliance with their local institutional review board requirements. After
informed consent was obtained, serum samples and clinical data were collected daily for up to
7 consecutive days. Sample collection ended when one of the following events occurred: the
subject was discharged, transplanted, died, or completed the 7th study day. Serum samples
were stored frozen at -70° until testing.
The Chronic Liver Disease (CLDD; PI–William M. Lee, MD) and the Nucleic Acid, Serum,
and Tissue Repository for the Study of Liver Diseases Database and sample repositories
(NSTLD; PI–Marlyn Mayo, MD) are principal investigator-initiated studies at UT Southwestern Medical Center (UTSW) in Dallas, TX. After written informed consent was obtained, sera
were obtained and frozen at -70° until testing.
This retrospective analysis received Institutional Review Board (IRB) approval from the
University of Texas Southwestern Medical Center (IRB#STU092010-126) and Virginia Commonwealth University (IRB#HM13517).
All study subjects were categorized into infection groups using modified definitions from
the 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference definitions of systemic inflammatory response syndrome (SIRS), severe sepsis, and septic shock [9,
10, 16] based upon available data from the USALFSG database. Subjects with SIRS had to have
two or more of the following signs or symptoms: body temperature >38°C or <36°C, heart
rate >90 bpm, respiration rate >20 breaths/min, PCO2 level <32 mm Hg, WBC >12,000 or
<4,000, or bands (immature granulocytic white blood cells) >10%. Severe sepsis was defined as
organ failure in the presence of sepsis (SIRS plus a documented infection defined as a positive
culture (blood, trachea, wound, catheter or urine) up to 2 days prior to the blood sample). Septic shock was defined as the presence of severe persistent hypotension (mean arterial pressure
<60 mmHg) despite adequate volume resuscitation and pressor therapy in the presence of sepsis [16]. Non-infected/non-SIRS (non-SIRS) samples were selected from patients who met no
more than one of the SIRS criteria.
For the 1,863 patients enrolled in the ALF study, 12,492 days of demographic and bio-data
were sorted into 1 of the 4 groups: non-SIRS (n = 628), SIRS (n = 1407), severe sepsis
(n = 387), and septic shock (n = 31). Because the USALFSG is an observational study not specifically designed to study SIRS or infections, some data parameters noted in the 4 different
SIRS categories were either not captured by the ALF CRF or were not routinely collected on all
patient days (examples: cell differential, urine output, tachypnea, and cardiac index). Thus,
each patient day was categorized into a SIRS category based upon available data (i.e., if a lab
value was missing, it was considered to be negative for that parameter and, if present, considered positive if the parameter met positive criteria). Samples for the non-SIRS category were
only selected from days that had all available data and were negative for each parameter. Once
sorted into the 4 SIRS categories, 115 subjects were randomly selected, based upon sample
availability and maintaining a balance between the etiologies of their acute liver failure (acetaminophen toxicity, viral hepatitis or other etiologies). Currently, 46% of all ALF cases (in both
the USALFSG and the US) result from APAP toxicity, either suicidal overdoses or unintentional excessive dosing [15]. To ensure a balanced distribution of etiologies, an equal number
of samples were requested for each etiology.
In addition, 10 subjects from each of the CLDD and NSTLD repositories were randomly
selected as negative controls. These subjects were ambulatory patients with CLD who had provided a screening blood sample during a routine clinic visit without symptoms. Limited biodata were available for this group. These subjects were considered to be non-SIRS and had no
clinical or laboratory evidence of bacterial infection.
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Immunoassay testing
The ADVIA Centaur BRAHMS PCT assay [17] is a sandwich immunoassay utilizing a monoclonal mouse antibody to fluorescein covalently linked to paramagnetic particles, a monoclonal
mouse antibody to procalcitonin that is labeled with acridinium ester and a second monoclonal
mouse antibody to procalcitonin labeled with fluorescein.
All testing was performed at Siemens Healthcare Diagnostics in Tarrytown, NY on a single
ADVIA Centaur. Siemens Healthcare Diagnostics, Tarrytown, NY, provided all reagents
required for testing.

Statistical Analyses
Descriptive statistics (median and range) are provided for all analyzed samples by group. A
Kruskal-Wallis test with post hoc testing (Dunn Method) was used to determine the utility of
PCT to detect infection, to examine possible measurement differences in PCT between patients
with CLD and ALF, and to determine the existence of a dose affect between PCT values and
severity of infection in ALF patients [18]. A Chi-square test was used as an alternative method
for analyzing patient groups and infection status. PCT values were categorized into infection
and non-infection groups using ROC analyses [19]. A 2-way analysis of variance was performed to examine the difference in PCT by type of culture (blood vs. all other culture types),
severity categories (severe sepsis and septic shock), and the interaction of these two factors.
The median PCT values for the CLD, non-SIRS, and SIRS groups were compared to the reference range of the PCT assay. An expected reference value of <0.1 ng/mL had been previously
calculated from PCT values from a population of 456 normal subjects. The 95% confidence
interval for the mean concentration was 0.023 to 0.028 ng/mL [17]. SPSS version 20.0 (SPSS,
Chicago, IL) and SAS version 9.2 (Cary, NC) were used for statistical analyses.

Results
Study group characteristics based upon disease severity
Available demographic and laboratory data for the 115 study subjects and control groups are
shown in Tables 1 and 2. No discernible differences were apparent between the groups studied,
except that the CLD group was somewhat older and the overall ALF group contained more
women. Laboratory and certain clinical values differed significantly across the various study
groups generally reflecting severity of illness: WBC, platelets, INR, AST, ALT, creatinine, lactate, pO2, O2 saturation, pCO2, pulse, respiration, and MAP.
Within the group of 115 ALF patients examined, all 56 with severe sepsis or septic shock
had demonstrated positive bacterial cultures (Table 1), and the CLD, non-SIRS, and SIRS
groups had no reported positive cultures on or prior to the study day. Blood stream infections
(with or without other positive cultures) were present in 23 of the 56, with the majority of the
remaining infections being tracheal, urinary tract or multiple without blood stream infection
(n = 16, 8 and 4 respectively).
Fig 1 and Table 2 present the median results for the PCT assay across all categories.
There was a significant difference between the CLD, non-SIRS and SIRS groups with a Chisquare = 43.68 (df = 2, p-value <0.001) as well as between the CLD group and either the nonSIRS or the SIRS groups (both p-values <0.001). However, there was no significant difference
between the non-SIRS and SIRS groups (p-value >0.05). When PCT results for CLD, nonSIRS, and SIRS groups combined were compared to the documented reference value of the
PCT assay (<0.1 ng/mL—(17)), the median PCT value (0.97 ng/mL) was significantly higher
than the reference value (p <0.001). Results for the CLD group (median = 0.104 ng/mL)
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Table 1. Demographic Data for Patients Based Upon Severity of Illness Classifications.
Mean (± SD) or
Number (%)

CLD
n = 20

non-SIRS
n = 30

SIRS
n = 29

Severe Sepsis
n = 40

Septic Shock
n = 16

p-value

51 (29–71)

49 (19–86)

37 (18–66)

41 (17–73)

41 (19–71)

0.044

10 (50)

15 (50)

21 (72.4)

33 (82.5)

12 (75)

0.019

5 (16.7)

5 (17.2)

5 (12.5)

1 (6.7)

14 (77.8)

21 (66.7)

23 (79.3)

33 (82.5)

14 (87.5)

African American

1 (5.6)

5 (16.7)

5 (17.2)

4 (10.0)

1 (6.2)

Asian

2 (11.1)

2 (6.7)

1 (3.4)

2 (5.0)

1 (6.2)

Age (years)
Gender
Female
Ethnicity*
Hispanic
Race**
White

0.672

Hawaiian
Other

1 (3)
1 (5.6)

1 (3)

1 (2.5)

Diagnosis
APAP

10 (33.3)

10 (34.5)

16 (40.0)

Viral Hepatitis

10 (50)

10 (33.3)

10 (34.5)

7 (17.5)

5 (31.2)
1 (6.2)

Other

10 (50)

10 (33.3)

9 (31.0)

17 (42.5)

10 (62.5)
1 (6.2)

Outcome (TFS)
APAP

6 (20)

5 (17.2)

12 (30.0)

Viral Hepatitis

4 (13.3)

2 (6.9)

2 (7.4)

Other

1 (3.3)

4 (13.8)

5 (12.5)

1 (6.2)

Coma Grade
Not Reported / 0

20 (100)

4 (13.8)

3 (7.5)

1 (3.4)

4 (10.0)

1

11 (36.7)

2

11 (36.7)

8 (27.6)

1 (2.5)

3

4 (13.3)

5 (17.2)

11 (27.5)

1 (6.2)

4

4 (13.3)

11 (37.9)

21 (52.5)

15 (93.8)

Culture Types
Blood

6

5

Tracheal

12

4

Urine

5

3

Wound

3

1

Catheter

1

Multiple w Blood

10

Multiple w/o Blood

2

3

1

19 (63.3)

23 (79.3)

33 (82.5)

13 (81.2)

Prophylaxis

15 (50)

17 (58.6)

19 (47.5)

10 (62.5)

0.673

Therapy

7 (23)

12 (41.4)

22 (55.0)

7 (43.8)

0.069

7 (2–13)

7 (2–13)

6 (2–13)

6.5 (2–11)

0.872

2 (0–11)

3 (0–51)

2 (0–22)

3 (0–16)

0.557

Antibiotics Used

Age of Sample (years)
After Hospital Admission (days)

9 (1–15)

0.294

*Ethnicity: O were reported in the CLD group; 15 of 16 were reported in the Septic Shock group
**Race: 18 of 20 reported in the CLD group / p-value reported for white vs. all other races.
doi:10.1371/journal.pone.0138566.t001

considered separately did not differ from the published reference range (p = 0.985), while
results from each of the other two groups (non-SIRS–median = 1.57 ng/mL and SIRS–
median = 2.29 ng/mL) were significantly higher than the reference and the CLD median value
(p <0.001 for both).
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When PCT concentrations were compared across all categories, there was a significant difference between the CLD group and the four ALF categories (Chi-square = 53.98, p-value <0.001).
Post hoc pairwise testing indicated that the median PCT of the CLD group was significantly different from each of the ALF categories (p<0.001). However, there were no significant differences
observed (p = 0.169) between the four ALF categories themselves (non-SIRS, SIRS, severe sepsis
and septic shock). When we compared the PCT values between ALF subjects without a documented infection (non-SIRS and SIRS) to those with a documented infection (severe sepsis and
septic shock), there was no difference between the 2 groups (p = 0.082).
Subjects in severe sepsis and septic shock categories were examined based upon types of cultures: blood cultures vs. all other culture types. There were no significant differences observed
for any of the 3 interactions: type of culture (p = 0.224), severity categories (p = 0.309), or the
interaction between these two factors (p = 0.241). There was also no difference observed
between the median PCT levels for subjects with positive blood cultures and those with positive
cultures from other sources.

Study group characteristics based upon PCT cut-off value
In previous studies, values of PCT above 2.0 ng/mL were considered to be associated with bacterial infection. While our non-SIRS and SIRS categories lacked evidence of infection, both
demonstrated median PCT values near or slightly above the 2.0 ng/mL cut-off, 1.57 and 2.29
respectively. Given the uncertainty concerning what a reasonable cut-off value for infection
should be for this population, we used a receiver operator characteristic (ROC) analysis, in
Table 2. Biodata and Laboratory values for Patients Based Upon Severity of Illness Classifications.
Median

CLD
n = 20

non-SIRS
n = 30

SIRS
n = 29

Severe Sepsis
n = 40

Septic Shock
n = 16

p-value
<0.001

Pulse [bpm]

80

96

108

112

Respiration [breaths/min]

18

23

22

22

0.005

MAP [mmHg]

90.0

81.5

89.5

57.5

0.472*

Min Temp [°C]

36.6

35.9

36.5

36.0

0.200

Max Temp [°C]

36.8

36.7

37.4

34.3

0.101

Laboratory values
1.57

2.29

2.51

5.89

<0.001

AST [IU/L]

787

360

292

3069

<0.001

ALT [IU/L]

1894

775

750

1520

0.030

8.0

14.0

14.0

17.00

<0.001
0.002

PCT [ng/mL]

WBC [x 103 /uL]

0.104

Platelets[x 103 /uL]

143

88

115

61

Prothrombin time [secs]

27.5

25.0

21.0

25.0

0.124

INR [ratio]

3.0

2.0

2.0

3.0

0.030

Bilirubin [mg/dL]

15.0

10.0

10.0

12.5

0.902

Glucose [mg/dL]

122

103

110

145

0.997

Creatinine [mg/dL]

1.00

2.00

1.00

3.00

0.003

Lactate [mg/dL]

3.00

6.00

8.00

14.00

0.024

pO2 [mmHg]

117

86

107

93

0.025

pCO2 [mmHg]

34

27

27

25

<0.001

O2_saturation [%]

98

96

98

95

0.001

FiO2 [%]

28

40

40

50

0.056

pO2/FiO2 [ratio]

334

306.7

306.7

172.5

0.195

*Septic Shock was not included as MAP is deﬁned by the category.
doi:10.1371/journal.pone.0138566.t002
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Fig 1. Median PCT Values by Category. This graph represents the median PCT values for the five patient
severity groups. The lower dashed horizontal line represents the 0.1 ng/mL PCT cut-off value indicative of no
infection. The upper dotted horizontal line represents the 2.0 ng/mL PCT cut-off value indicative of severe
sepsis.
doi:10.1371/journal.pone.0138566.g001

which the optimal area under the curve (AUC) was equal to 0.697 (95% CI: 0.609–0.784), with
a cut-off value of 1.62 ng/mL, somewhat below the 2.0 ng/mL level (Fig 2). The cut-off value
determined from this set of data was made using a combination of criteria: 1) the point on the
curve that was at the greatest distance (0.186) from the 0.5 reference line at a 45° angle to the
line, 2) accuracy, 3) sensitivity (0.643), 4) specificity (0.620), and 5) likelihood ratio (1.693). We
used this 1.62 ng/mL cut-off for subsequent analyses.
When additional biochemical data ALF between subjects with a PCT that was <1.62 ng/mL
and from those with a PCT that was 1.62 ng/mL were compared, platelet, creatinine, AST,
ALT, and bilirubin showed significant differences between the theoretically ‘infected’ (above
the cut-off) and ‘non-infected’ (below the cut-off) groups (Table 3). Of interest, 85.4% of all
APAP subjects had values above the 1.62 ng/mL level while only 21 of 41 (51.2%) of the APAP
subjects had a documented bacterial infection. In the non-APAP subjects, 43.2% had values
above 1.62 ng/mL with documented bacterial infection in 35 of 74 (47.3%) of the subjects.
When PCT results were examined based solely upon etiology, median values for subjects
with APAP toxicity were typically much higher, between 3.0 and 6.6 times higher than the
results observed for the same severity category for subjects with non-APAP etiologies (Fig 3).

PLOS ONE | DOI:10.1371/journal.pone.0138566 September 22, 2015
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Fig 2. Receiver Operator Curve for the Detection of Infection in ALF and ALI patients Using PCT. The ROC analysis resulted in an AUC of 0.697 with a
sensitivity of 64.3% and a specificity of 62.0% for the use of PCT in the detection of infection this population of ALF patients.
doi:10.1371/journal.pone.0138566.g002

Discussion
In this study of ALF patients selected for increasing severity of SIRS features and for the presence of bacterial infection, PCT measurement disclosed markedly elevated values but did not
provide any direct correlation to presence or absence of infection. Determining the presence
with certainty of systemic infection in those with advance SIRS features is problematic in a retrospective study; we assumed that the presence of advanced SIRS features plus positive cultures
was the best surrogate for systemic infection and this may not be the case in every instance.
However, virtually all ALF subjects displayed PCT values well above both the 0.1 ng/mL reference value and the median value observed in the CLD controls, regardless of any evidence for
infection, particularly high values being observed in a large group that demonstrated no evidence for infection. The differences in PCT levels between severity categories among ALF
patients were not significant due apparently to elevated levels in the absence of infection. Thus,
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Table 3. Demographic and Biodata Results Based Upon the Calculated Infection Cut-off Value of 1.62 ng/mL.
PCTs < 1.62 ng/mL n = 48

PCT  1.62 ng/mL n = 67

APAP

6 (12.5)

35 (52.2)

Viral hepatitis

17 (34.7)

11 (16.4)

Other

25 (51.0)

21 (31.3)

APAP

3 (6.2)

21 (31.3)

Viral Hepatitis

5 (10.4)

3 (4.4)

Other

5 (10.4)

6 (9.0)

Median or Number (%)

p-value

ALF Etiology

Outcome (TFS)

0.6904

5.325

<0.001

WBC [x 103 /uL]

13.0

13.0

0.740

Platelets [x 103 /uL]

135

92

0.019
0.786

Procalcitonin [ng/mL]

INR [ratio]

2.0

2.0

115.5

120.0

0.787

Creatinine [mg/dL]

1.0

2.0

<0.001

AST [IU/L]

337

913

0.06

ALT [IU/L]

684

1759

0.07

Lactate [mg/dL]

3.5

6.0

0.230

Glucose [mg/dL]

Bilirubin [mg/dL]

19.0

7.0

<0.001

pO2 [mmHg]

92.5

103.0

0.707

pCO2 [mmHg]

29.0

27.0

0.108

84

68

0.084

Pulse [bpm]
Respiration [breaths/min]

17

13

0.094

Min Temp [°C]

36.0

37.0

0.298

Max Temp [°C]

37.0

37.0

0.298

Coma Grade
0 / Not reported

3

4

1

7

9

2

12

8

3

9

12

4

18

33

Samples were resorted based upon the cut-off value of 1.62 ng/mL and demographic and biodata were re-examined.
doi:10.1371/journal.pone.0138566.t003

both the non-SIRS and SIRS categories that would be expected to show low or normal PCT levels demonstrated PCT levels approximating those that have been observed previously in other
studies during active bacterial infection in a non-ALF setting.
Using a cut-off value determined by the ROC analysis, the presumed uninfected categories
(non-SIRS and SIRS) included 31 patients with elevated PCTs (1.62 ng/mL). Of these subjects, 13 demonstrated signs of infection (bacterial or fungal, n = 5 each) 1 or more days after
the PCT sample was collected or other evidence of infection upon closer examination of the
each subject’s case report form (CRF), including pancreatitis, tooth abscess or ventilator
acquired pneumonia with infiltrate on x-ray. Subjects with fungal infections were classified as
culture negative since values of PCT in yeast and fungal infections have been observed to be
lower than those seen with most bacterial infections [20].
The median PCT values in the severe sepsis and septic shock categories (3.46 ng/mL and
589 ng/mL, respectively), were both well above the 1.62 ng/mL calculated cut-off and 2.0 ng/
mL literature cut-off for severe sepsis [10], but these were not significantly different from the
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Fig 3. Median APAP vs All Other Etiologies PCT values by Category. This graph represents the median PCT values for the four ALF patient severity
groups sorted by etiologies: APAP and All Others etiologies (combined viral and other) with the lower dashed line indicative of no infection (0.1 ng/mL) and
the upper dotted line indicative of severe sepsis (2.0 ng/mL).
doi:10.1371/journal.pone.0138566.g003

median PCT values in non-SIRS and SIRS patients without documented infection. Of interest,
17 of 40 severe sepsis subjects and 3 of 16 septic shock subjects had PCT values below the 1.62
ng/mL cut-off. Prophylactic antibiotics might provide a partial explanation for lower PCT values during a documented infection but, overall, the decreased results remain unexplained. Full
bacterial culture reports were not collected as part of the USALFSG study nor did the study
case report forms capture information related to quantity of bacterial growth or antibiotic sensitivities that might have helped determine some the differences among the various severity
groups.
Upon examining results according to etiology, subjects with APAP toxicity demonstrated
much higher PCT levels than any other etiologies. It seems likely that the elevated PCT values
in these subjects are not indicative of infection. Rather, APAP toxicity unleashes an inflammatory response, with macrophage activation, release of cytokines and pro-inflammatory regulators including TNF-alpha that may secondarily contribute to liver injury and the appearance of
a septic milieu [21, 22]. While the exact origin and pathogenic pathway of PCT stimulation is
still unknown, it has been suggested that PCT is produced by neuroendocrine cells in the liver
while other data suggest that it is released by macrophages [23]. It is also possible that increases
in PCT may be initiated by TNF-alpha and IL-1b [24, 25]. It appears that in the acute liver failure setting PCT is increased due in large part to the massive inflammatory response to liver
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injury, particularly in the case of acetaminophen toxicity. While we did see higher PCT levels
in patients with bacterial infections, if PCT is to be useful in this population, a better understanding of the mechanism of PCT production will need to be ascertained.
Prior studies examining PCT values in the acute liver failure setting have been limited. Studies in patients with chronic liver disease (cirrhosis) [26–29], liver metastasis of non-liver primary solid tumors [23], and other acute and chronic liver diseases have been performed [30].
While baseline PCT values increased as the severity of the underlying liver disease increased,
an elevated PCT was indicative of bacterial infection. A previous study of PCT use in ALF
patients due to APAP toxicity also showed increased PCT values in subjects without evidence
of bacterial infection [14], similar to our findings.
We considered whether the use of older retrospective samples from the ALFSG repository
might affect results, since long-term sample storage may decrease observed PCT levels.
Schuetz, et al. studied two sets of samples that were stored at -80°C for 4.8 to 5.5 years and 3.3
to 4.6 years [31]. The PCTs for each set decreased by 11.4% and 13.5% respectively. Samples
used in this study had been stored an average of approximately 6.75 years at -80°C. While it is
assumed that the length of time in storage might have decreased the PCT values obtained, the
exact amount of decrease is unknown and an estimate of the extent of the effect cannot be calculated. However, since each sample group had similarly aged samples, this would appear to
negate a specific effect on the overall study results (Table 1).

Conclusion
Procalcitonin detects bacterial infection and sepsis in the general population, but appears to be
a more general marker of moderate to severe inflammation. As such, it has limited value as a
single marker to discriminate between the presence or absence of bacterial infection in the setting of acute liver failure but may be of value in combination with other markers. PCT elevations appeared to be roughly proportional to the degree of hepatic necrosis. A prospective
study with a larger sample size employing prospective determination of infection and standardized antibiotic usage might provide additional information regarding the relationship between
PCT and severe liver injury, particularly APAP toxicity.
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